The British Society for Rheumatology has moved toward a life course approach when updating guidelines for several rheumatic ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

Turning thet tide against tuberculosis . As the world's deadliest infectious disease surges, GSK and partners are pioneering ...

Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis. Click here to find out why ...

Endurance Techn, Solar Ind, GlaxoSmithKline, Gland, and Motilal Oswal marked their presence among the top gainers in the ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

Migraine is recognized globally as the seventh most disabling condition across all diseases, accounting for approximately 2.9% of all years lived with disability (YLDs). It is also the top cause of ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

The NIFTY MIDCAP 150's movements reflect ongoing market dynamics, with Global Health, JSW Infra, and GlaxoSmithKline ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.